A review of vitamin D and Parkinson's disease
Authors: Amie L Peterson
Journal: Maturitas (2014)
Discipline: CLINICAL MEDICINE
Keywords: Parkinson's disease; Vitamin D; Vitamin D receptor.
Affiliations: Oregon Health Sciences University, Mail Code: OP32, 3181, SW Sam Jackson Park Road, Portland, OR 97239, USA; Portland VA, 3710 SW US Veterans Hospital Road, Mail Code: P3PADRECC, Portland, OR 97239, USA. Electronic address: .

Abstract:  The role of vitamin D in bone health has been known for over a century. More recent research has suggested that vitamin D may play a role in the muscular, immune, endocrine, and central nervous systems. Animal research suggests that vitamin D may have some protective effects against toxic insults that are known to damage dopamine cells, the primary cells to degenerate in PD. Persons with PD tend to have lower vitamin D levels than persons of similar ages without PD. Vitamin D levels are generally associated with bone mineral density (BMD) in persons with PD, but simply giving vitamin D does not appear to improve BMD. Results of genetic studies examining polymorphism of the vitamin D receptor and PD risk, severity, or age at onset have shown variable results, with FokI CC seeming to possibly carry some increased risk of PD. Amount of sun exposure and vitamin D levels in earlier life may influence the risk of developing PD. Cross-sectional research suggests a relationship between vitamin D levels and severity of PD symptoms. A single intervention study did show some improvement in PD with vitamin D supplementation. Vitamin D may have effects on PD symptoms and perhaps even on the risk of disease development or disease progression. More well designed intervention studies are needed to confirm the effect of vitamin D on PD symptoms. Human neuroprotection studies are needed, but probably not feasible until better biomarkers are established. 

Retracted: No

PubPeer comments:
 Fig 2A.  Colony formation assay of HepG2 cells: A u2013 inhibition of colony formation . ![] 25 and 50 microM panels are the same. For comparison: Fig 1C from [Chen et al (2019)] . ![] Fig 3 from [Zhang, Li Ji (2018)] , and Figure 1C from [Huang, Xie Liu (2019)] . ![] , 
 #1 After I posted the marked figure, just saw, although you didn t mark it, you did describe in your text. ![file] , 
 *[left]* Figure 5 from [Zhang, Bao Yang (2019)] .  Detection of apoptosis by DAPI staining at indicated doses of genistein . *[right]* Fig 3 from [Duan et al (2019)] .  Figure 3. Mulberroside-A induces dose-dependent apoptotic cell death as indicated by DAPI staining. The upper two-thirds of each panel from the left is also the lower half of a panel from the right. ![file] , 
 Figure 7.  The effect of indicated doses of genistein on the expression of caspase-dependent mitochondrial apoptosis pathway proteins in HepG2 cells. Representative images of cytochrome c, Bax, Bcl-2, PARP, cleaved caspase 9 and cleaved caspase 3 protein expression detected by western blot. u03b2-actin was used as a control. ![] For comparison: *[left]* Figure 5 from [Li, Yang Shen (2019)] .  The effect of indicated doses of gentiopicroside on Bax and Bcl-2 expression as indicated by western blotting. *[middle]* Figure 5 from [Deng Li (2019)] .  Effect of linderalactone on the cell cycle phase distribution of A549 cells as depicted by Western blotting. *[right]* Fig. 7 from [Bi et al (2018)] .  Effect of indicated doses of genistein ... (B) protein expression of survivin, cyclin D1 and ALDH1A1 . ![] , 
 #3 Fig 5 again *[left]]* ![] Another sighting! Fig 4 from [Zhang et al (2018)] : ![] , 
 #4 Fig 7 again *left]*. The PARP band appears to come from Fig 5D of [Bi et al (2018)] *[right]*. ![file] ,